Advancing Bacteriophage for the Treatment of Bacterial Infections

AmpliPhi BioSciences Corporation is advancing the fight against antibiotic resistance through the development of innovative antibacterial solutions. We invite you to learn more about our proprietary bacteriophage technology and the promise it holds for combating critical health issues facing society.

Antibiotic Resistance -
A Global Health Threat

Antibiotic resistance is one of the most pressing health issues facing the world today. Increasing antibiotic resistance levels are creating an environment in which even commonplace infections could again cause high mortality rates as was the case before the advent of widespread antibiotic usage.

Harnessing Viruses in the
War Against Disease

AmpliPhi seeks to employ the power of highly specific bacteriophages to fight infection. The Company’s proprietary approach utilizes bacteriophages, naturally occurring viruses that target and destroy infecting bacteria.

Lead Therapeutic Programs Targeting Otitis and Cystic Fibrosis

AmpliPhi is the first company to advance Bacteriophage Technology through a double-blind Phase 1/2 clinical trial. The Company’s primary programs include BioPhage-PA for the treatment of Pseudomonas aeruginosa infections that occur in chronic ear infections and BioPhage-PR, for the treatment of Pseudomonas lung infections in cystic fibrosis patients.

Advancing Bacteriophage for the Treatment of Bacterial Infections

AmpliPhi BioSciences Corporation is advancing the fight against antibiotic resistance through the development of innovative antibacterial solutions. We invite you to learn more about our proprietary bacteriophage technology and the promise it holds for combating critical health issues facing society.

AmpliPhi and SPS Together -
the global leader in developing phage therapy for treating infectious disease.

Now trading as AmpliPhi, The enlarged company combines complementary technologies and expertise in bacteriophage-based therapies to create an exciting development-stage pipeline of innovative anti-bacterials addressing the rapidly growing global market treating antibiotic resistant infections.